All
Real-World Data May Support Opdivo Plus Yervoy Efficacy in mRCC
Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.
Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.
My Top 10 Hacks for Surviving with Cancer in the Infusion Room
Every treatment bag should include an unlimited supply of humor. Stuff will happen. It’ll be hard, but you may learn to laugh about it later, like I did.
Psilocybin May Have Mental Health Benefits for Patients With Cancer
CURE spoke with an expert about the potential positive effects of psilocybin-assisted psychotherapy.
BLA Has Been Submitted For Kidney Cancer Imaging PET Product Zircaix
A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.
Retiring Shouldn’t Mean Resigning: The Power of Speaking Up About Your Advanced Prostate Cancer Treatment Options
Coming to Terms With Hair Loss After Chemotherapy
Losing my hair after chemo was devastating, and I struggled to accept how it changed my appearance and self-image.
Stereotactic Body Radiation May Improve Survival in Liver Cancer Subset
Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.
A Year of Resilience: Looking Back After a Myeloma Diagnosis
2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.
CBD Use Found to Be Safe Among Patients with Breast Cancer, Prompts Further Study
CBD consumption was safe but did not have a statistically significant reduction in scan-related anxiety versus placebo for patients with breast cancer.
Short-Course Radiation Aids Survival in Older Patients With Glioblastoma
18F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly diagnosed glioblastoma.
Understanding the Intricacies of CAR-T Cell Therapy and Care in Hematologic Malignancies
Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.
Cisplatin-Based Chemo Regimen May Improve Survival in Bladder Cancer
Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder cancer.
Remembering the Lessons of a Cancer Diagnosis
After surviving colon cancer, I reflect on how the lessons from my journey transformed my life and guide me to embrace its beauty.
Veliparib and Temozolomide Combo Does Not Significantly Extend Survival for Patients With Glioma
Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.
Putting an Emphasis on Patient Collaboration in MPN Treatment
Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm diagnosis.
Nurses Leading the Way in Cancer Care
Emily Armstrong, Rose Sawyer and Ruth Cummings, oncology nurses, are recognized for their dedication, expertise and patient advocacy at Denver Health.
FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC
The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell lung cancer.
FDA Reviews NDA for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.
AYA Patients With Cancer, ‘In Between’ Kids and Adults, Face Unique Concerns
Ann Graham of MIB Agents discussed some of the challenges adolescent and young adult patients deal with after cancer diagnoses.
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.
Embracing Change in the Face of Aging and Breast Cancer
I've learned to embrace the changing nature of my body as I age, accepting the challenges and finding gratitude in each day.
Greg Gumbel Died of Cancer, Olympian Gabriela Dabrowski Competed During Treatment and More
From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here is the latest cancer news.
Top Lung Cancer Stories in 2024
CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.
FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
Chemotherapy May Be Safe and Effective for Pregnant Patients With Breast Cancer
An expert explained recent findings from a study of pregnant women with breast cancer who underwent chemotherapy and fared better than nonpregnant patients.
Survivor’s Guilt: Asking, ‘Why Me?’
Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.
Cancer Therapies Approved by the FDA in December 2024
The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.
A Commitment to New Therapies for MPN Despite Scientific Challenges
One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.
